EGFR and non-small cell lung carcinoma: Moreover, researchers have reported that individuals with NSCLC, EGFR mutations, and brain metastasis can experience stronger improvements after receiving both icotinib and WBRT/SRS compared with icotinib alone (31.9 vs. 27.9 months, p = 0.237).